Prostatype Genomics AB (OSTO:PROGEN) Total Debt per Share: kr0.03 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:PROGEN Prostatype Genomics AB OSTO:PROGEN
23 GF Score
Price kr0.18
GF Value kr0.04
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Prostatype Genomics AB Total Debt per Share?

Prostatype Genomics AB OSTO:PROGEN -1.67% 23 Total Debt per Share is kr0.03 as of Dec. 2025. GuruFocus rates OSTO:PROGEN with a GF Score™ of 23/100 and a GF Value™ of kr0.04 (Significantly Overvalued). The stock has 5 warning signs investors should review.

kr0.03 (As of Dec. 2025)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Prostatype Genomics AB's Total Debt Per Share for the quarter that ended in Dec. 2025 was kr0.03.

Prostatype Genomics AB Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB Total Debt per Share Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial 1.75 0.79 6.10 0.00 0.03

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.10 0.00 0.00 0.00 0.03
OSTO:PROGEN
23GF Score
Prostatype Genomics AB OSTO:PROGEN
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostatype Genomics AB Total Debt per Share Calculation

Prostatype Genomics AB's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.00+5.30)/155.57
=0.03

Prostatype Genomics AB's Total Debt Per Share for the quarter that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.00+5.30)/155.57
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of kr0.03 mean?
Prostatype Genomics AB (OSTO:PROGEN) has a Total Debt per Share of kr0.03 as of Dec. 2025. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Prostatype Genomics AB and its competitors.
Is Prostatype Genomics AB's Total Debt per Share too high?
Prostatype Genomics AB's current Total Debt per Share is kr0.03. Overall, Prostatype Genomics AB has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Total Debt per Share compare to TMO and DHR?
Prostatype Genomics AB's Total Debt per Share of kr0.03 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Medical Diagnostics & Research company?
A good Total Debt per Share depends on the Medical Diagnostics & Research industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current Total Debt per Share is kr0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.04, compared to a current price of kr0.18 — trading 342.5% above its estimated fair value. The current Total Debt per Share is kr0.03. Prostatype Genomics AB's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Total Debt per Share is kr0.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued. The current stock price of kr0.18 is trading 342.5% above its estimated GF Value™ of kr0.04. GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.

Key valuation signals for OSTO:PROGEN:

  • Total Debt per Share: kr0.03
  • GF Value™: kr0.04 vs. price of kr0.18 (342.5% above fair value)
  • GF Score™: 23/100 with 5 warning signs

No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prostatype Genomics AB Business Description

Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
23GF Score

Get the complete analysis for OSTO:PROGEN

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.18
Price
kr0.04
GF Value